Oak Thistle LLC Invests $1.72 Million in Labcorp Holdings Inc. $LH

Key Points

• Oak Thistle LLC opened a new position in Labcorp in Q4, buying 6,848 shares worth roughly $1.72 million.
• Recent results and guidance: Labcorp beat EPS expectations ($4.07 vs. $3.95), reported revenue up 5.6% YoY to $3.52B, and set FY2026 guidance of $17.55–$18.25 EPS.
• Market sentiment and ownership: Analysts have a consensus "Moderate Buy" with an average target of $307.70, institutional ownership is about 95.9%, and insiders have been net sellers (16,113 shares sold, ~$4.55M).

Oak Thistle LLC acquired a new position in shares of Labcorp Holdings Inc. (NYSE:LH - Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 6,848 shares of the medical research company's stock, valued at approximately $1,718,000.

Other hedge funds have also modified their holdings of the company. HBK Sorce Advisory LLC lifted its stake in Labcorp by 4.3% during the 3rd quarter. HBK Sorce Advisory LLC now owns 916 shares of the medical research company's stock worth $254,000 after acquiring an additional 38 shares in the last quarter. Pure Financial Advisors LLC lifted its stake in Labcorp by 3.9% during the 3rd quarter. Pure Financial Advisors LLC now owns 1,017 shares of the medical research company's stock worth $292,000 after acquiring an additional 38 shares in the last quarter. Hantz Financial Services Inc. lifted its stake in Labcorp by 48.8% during the 3rd quarter. Hantz Financial Services Inc. now owns 122 shares of the medical research company's stock worth $35,000 after acquiring an additional 40 shares in the last quarter. Burney Co. lifted its stake in Labcorp by 0.5% during the 3rd quarter. Burney Co. now owns 8,819 shares of the medical research company's stock worth $2,532,000 after acquiring an additional 42 shares in the last quarter. Finally, Advisor OS LLC increased its holdings in Labcorp by 5.4% during the 3rd quarter. Advisor OS LLC now owns 821 shares of the medical research company's stock worth $236,000 after purchasing an additional 42 shares during the period. 95.94% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on LH. Weiss Ratings upgraded Labcorp from a "hold (c+)" rating to a "buy (b-)" rating in a report on Tuesday, February 10th. Piper Sandler upped their price target on Labcorp from $270.00 to $300.00 and gave the stock a "neutral" rating in a report on Tuesday, February 24th. Robert W. Baird upped their price target on Labcorp from $313.00 to $326.00 and gave the stock an "outperform" rating in a report on Wednesday, February 18th. JPMorgan Chase & Co. upped their price target on Labcorp from $319.00 to $330.00 and gave the stock an "overweight" rating in a report on Wednesday, February 18th. Finally, Wall Street Zen downgraded Labcorp from a "buy" rating to a "hold" rating in a report on Saturday, April 4th. Eight analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company's stock. According to data from MarketBeat, Labcorp currently has a consensus rating of "Moderate Buy" and an average target price of $307.70.

Labcorp Trading Up 2.2%

LH opened at $275.10 on Thursday. Labcorp Holdings Inc. has a one year low of $209.38 and a one year high of $293.72. The company has a market cap of $22.67 billion, a P/E ratio of 26.30, a PEG ratio of 1.87 and a beta of 1.02. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.23 and a current ratio of 1.42. The business's 50-day simple moving average is $274.52 and its 200-day simple moving average is $268.89.

Labcorp (NYSE:LH - Get Free Report) last released its quarterly earnings data on Tuesday, February 17th. The medical research company reported $4.07 EPS for the quarter, beating analysts' consensus estimates of $3.95 by $0.12. Labcorp had a return on equity of 16.16% and a net margin of 6.28%.The business had revenue of $3.52 billion for the quarter, compared to the consensus estimate of $3.56 billion. During the same quarter in the prior year, the business posted $3.45 EPS. The business's revenue for the quarter was up 5.6% on a year-over-year basis. Labcorp has set its FY 2026 guidance at 17.550-18.250 EPS. As a group, equities research analysts expect that Labcorp Holdings Inc. will post 16.01 EPS for the current fiscal year.

Labcorp Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 12th. Stockholders of record on Friday, February 27th were issued a $0.72 dividend. The ex-dividend date was Friday, February 27th. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.0%. Labcorp's dividend payout ratio is presently 27.53%.

Insiders Place Their Bets

In other news, CEO Adam H. Schechter sold 8,705 shares of the stock in a transaction dated Tuesday, March 3rd. The stock was sold at an average price of $279.96, for a total value of $2,437,051.80. Following the transaction, the chief executive officer owned 80,773 shares in the company, valued at approximately $22,613,209.08. This represents a 9.73% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Jonathan C. Meltzer sold 87 shares of the stock in a transaction dated Thursday, February 12th. The shares were sold at an average price of $290.42, for a total value of $25,266.54. Following the completion of the transaction, the executive vice president owned 2,782 shares in the company, valued at approximately $807,948.44. The trade was a 3.03% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 16,113 shares of company stock worth $4,547,450. Insiders own 0.84% of the company's stock.

About Labcorp

Laboratory Corporation of America Holdings, commonly known as Labcorp NYSE: LH, is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp's core businesses encompass clinical laboratory testing and pharmaceutical development services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.